Spatial analysis finds immune-rich pockets in diffuse large B-cell lymphoma tumors with clear treatment potential
Study identified seven distinct and unique microenvironments within diffuse large B-cell lymphoma (DLBCL)
Immune-privileged DLBCLs contain many T cells mixed with tumor B cells and show signs that those T cells are active and ready to attack
Study is a key milestone toward understanding how tumors and a patient’s immune system interact to shape treatment outcomes
By analyzing the tumor environment of diffuse...
Researchers identify genetic markers that affect treatment outcomes in patients with large B-cell lymphoma
Multiple genetic markers play a key role in the treatment outcomes of patients with large B-cell lymphoma (LBCL) who received chimeric antigen...
Stem cell transplant achieves positive outcomes in second remission for adolescents and young adults with ALL
A new study from Â鶹ӳ» MD Anderson Cancer Center and Dana-Farber Cancer Institute, published in American Journal of Hematology...
Patients receiving anti-cancer treatment near end of life experience higher rates of hospitalization, ED and ICU use, and less utilization of hospice
Patients who receive systemic anti-cancer treatment near end of life are more likely to be hospitalized, go to the intensive care unit or emergency department, and are less likely to utilize hospice care in the final 30 days of life, according to researchers at Â鶹ӳ» MD Anderson Cancer Center. This pattern of care was observed in patients who received all types of systemic anticancer therapy, including cytotoxic...
